Among these, E2F1 is the first member of the E2Fs to be discovered that could bind both to Rb to exhibit tumor-suppressive effects [13], and induce tumorigenesis, drug resistance, and other adverse outcomes through its role as a transcriptional activator [14, 15]. Here, E2F1 is linked to neoplasm.